Allergan plc (NYSE:AGN) – Equities research analysts at SunTrust Banks decreased their Q4 2018 EPS estimates for Allergan in a research note issued on Monday, October 15th. SunTrust Banks analyst J. Boris now anticipates that the company will earn $4.09 per share for the quarter, down from their prior forecast of $4.10. SunTrust Banks has a “Buy” rating and a $218.00 price objective on the stock.

Allergan (NYSE:AGN) last announced its earnings results on Thursday, July 26th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the prior year, the company earned $4.02 EPS. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year.

AGN has been the subject of a number of other reports. Zacks Investment Research cut shares of Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 3rd. ValuEngine upgraded shares of Allergan from a “strong sell” rating to a “sell” rating in a research note on Friday, September 21st. TheStreet upgraded shares of Allergan from a “d+” rating to a “c” rating in a research note on Monday, August 20th. Cowen set a $255.00 target price on shares of Allergan and gave the stock a “buy” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $180.00 target price on shares of Allergan in a research note on Friday, September 14th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have given a buy rating to the stock. Allergan has an average rating of “Buy” and an average price target of $211.91.

AGN stock opened at $191.00 on Wednesday. Allergan has a 52 week low of $142.81 and a 52 week high of $197.33. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85. The firm has a market cap of $64.66 billion, a price-to-earnings ratio of 11.68, a price-to-earnings-growth ratio of 1.47 and a beta of 1.19.

Several institutional investors and hedge funds have recently bought and sold shares of AGN. LPL Financial LLC lifted its stake in shares of Allergan by 27.9% in the 1st quarter. LPL Financial LLC now owns 65,487 shares of the company’s stock valued at $11,021,000 after purchasing an additional 14,282 shares during the period. Moors & Cabot Inc. increased its holdings in Allergan by 33.4% in the 1st quarter. Moors & Cabot Inc. now owns 11,963 shares of the company’s stock worth $2,013,000 after acquiring an additional 2,998 shares in the last quarter. Financial Partners Capital Management LLC increased its holdings in Allergan by 1.3% in the 1st quarter. Financial Partners Capital Management LLC now owns 53,521 shares of the company’s stock worth $9,007,000 after acquiring an additional 691 shares in the last quarter. Cypress Capital Group purchased a new stake in Allergan in the 1st quarter worth $247,000. Finally, Summit Trail Advisors LLC increased its holdings in Allergan by 13,646.4% in the 1st quarter. Summit Trail Advisors LLC now owns 1,199,371 shares of the company’s stock worth $1,199,000 after acquiring an additional 1,190,646 shares in the last quarter. Hedge funds and other institutional investors own 77.38% of the company’s stock.

In other news, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was purchased at an average cost of $190.64 per share, for a total transaction of $1,906,400.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Joseph H. Boccuzi bought 900 shares of the firm’s stock in a transaction that occurred on Thursday, August 30th. The stock was purchased at an average price of $190.59 per share, with a total value of $171,531.00. The disclosure for this purchase can be found here. Insiders own 0.37% of the company’s stock.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

See Also: What is the Dividend Aristocrat Index?

Earnings History and Estimates for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.